BCICX | JNBCX | BCICX / JNBCX | |
Total Expense Ratio | 1.57 | 1.25 | 126% |
Annual Report Gross Expense Ratio | 1.69 | 1.57 | 108% |
Fund Existence | 17 years | 18 years | - |
Gain YTD | 6.531 | 7.561 | 86% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 1000 | 100% |
Min. Initial Investment IRA | 100 | N/A | - |
Net Assets | 10.5B | 8.35B | 126% |
Annual Yield % from dividends | 4.92 | 5.14 | 96% |
Returns for 1 year | 9.21 | 10.47 | 88% |
Returns for 3 years | 23.39 | 22.36 | 105% |
Returns for 5 years | 22.47 | 20.91 | 107% |
Returns for 10 years | 43.36 | 44.15 | 98% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
ASVIX | 10.10 | 0.06 | +0.60% |
American Century Small Cap Value Inv | |||
VSTSX | 300.61 | 1.32 | +0.44% |
Vanguard Total Stock Mkt Idx Instl Sel | |||
GSLLX | 23.27 | 0.09 | +0.39% |
Goldman Sachs Enhanced U.S. Equity Inv | |||
PXIIX | 22.47 | 0.07 | +0.31% |
Virtus KAR Equity Income I | |||
FBTTX | 25.58 | N/A | N/A |
Fidelity Advisor Biotechnology M |